Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1151-1160 Newer>

Managed Care April 2004	Pharmacy Directors See Healthy Increase in Pay in 2003 Salaries of pharmacy directors in 2003 were up substantially from 2002.
Managed Care April 2004 Michael S. Victoroff	There's No Such Thing As 'Futile Care Theory' Discussing differing viewpoints brings a rich complexity to a rational exchange about whether it's ever right to deny life-saving treatment against someone's will.
Managed Care April 2004 Thomas Morrow	Transdermal Patches Are More Than Skin Deep After modest beginnings, transdermal patches are now taking advantage of nanotechnology and other novel techniques to improve drug delivery.
The Motley Fool April 30, 2004 Charly Travers	Sales Weakness From InterMune Biotechnology company InterMune would seem to be in good shape with a drug, Actimmune (which helps boost the immune system of cancer patients and others). The drug, however, has been showing quarterly sales weakness since early 2003, a trend that now seems like it may continue into the future.
InternetNews April 29, 2004 Susan Kuchinskas	Health Could Mean Wealth for Microsoft A partnership with WellPoint Health Networks aims to persuade doctors to go wireless on PocketPCs.
The Motley Fool April 29, 2004 Bill Mann	Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses.
The Motley Fool April 29, 2004 Charly Travers	MedImmune's Big Gamble FluMist may not be worth the gigantic R&D investment.
The Motley Fool April 29, 2004 Brian Gorman	Merck, Bristol-Myers Team Up Their agreement to commercialize a diabetes drug reflects intense sales competition in the industry.
The Motley Fool April 28, 2004 Glen Trematore	Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers.
The Motley Fool April 27, 2004 Alyce Lomax	Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux.
<Older 1151-1160 Newer> Return to current articles.